U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07825207) titled 'Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms' on Sept. 11.
Brief Summary: Hypocellular myelodysplastic neoplasms (h-MDS) are a distinct entity introduced in the 2022 WHO classification. They are characterized by reduced bone marrow cellularity and may share several clinical, morphological, immunological, and molecular features with aplastic anemia (AA), making the differential diagnosis between the two conditions challenging.
Eltrombopag, a thrombopoietin receptor agonist, has demonstrated efficacy in patients with severe AA and has also shown activity in lower-risk MDS, with bone marrow hypocellula...